← Eichor
Condition: Myelosuppression Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Myelosuppression

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06245746Autologous Hematopoietic Stem Cell Boost Study After CAR-T Therapy
Phase 2 · 1 location(s) · Ruijin Hospital · NCT06589089Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Tr
Phase 2 · 1 location(s) · Shanghai Chest Hospital · NCT06698965A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Table
Phase 4 · 1 location(s) · Hongxia Wang · NCT07578064Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
Phase 2 · 1 location(s) · Affiliated Hospital of Nantong University · NCT07205536Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06992739Trilaciclib Prevents Myelosuppression With Chemoradiotherapy
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06490081Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) Durin
Phase 4 · 1 location(s) · Marco Schiuma · NCT07477119Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Phase 4 · 1 location(s) · Pharmacosmos A/S · NCT05874401A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patie
Phase 2 · 1 location(s) · Fudan University · NCT06699472Study of Trilaciclib and Lurbinectidin
Phase 2 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT05578326Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06929936Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
Phase N/A · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06698692
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.